Comparing Adherence and Persistence Across 6 Chronic Medication Classes

被引:471
作者
Yeaw, Jason [1 ]
Benner, Joshua S. [2 ]
Walt, John G. [3 ]
Sian, Sergey [1 ]
Smith, Daniel B. [1 ]
机构
[1] IMS Hlth, Watertown, MA 02472 USA
[2] Brookings Inst, Engelberg Ctr Hlth Care Reform, Washington, DC 20036 USA
[3] Allergan Pharmaceut Inc, Global Hlth Outcomes Strategy & Res, Irvine, CA 92715 USA
来源
JOURNAL OF MANAGED CARE PHARMACY | 2009年 / 15卷 / 09期
关键词
OVERACTIVE BLADDER; URINARY-INCONTINENCE; GLAUCOMA MEDICATIONS; ELDERLY PATIENTS; STATIN THERAPY; POPULATION; COSTS; RISK; PRESCRIPTIONS; INTERVENTIONS;
D O I
10.18553/jmcp.2009.15.9.728
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: The National Quality Forum recently endorsed the proportion of days covered (PDC)-a measure of medication adherence-as an indicator of quality in drug therapy management. OBJECTIVE: To inform initial efforts to improve the quality of drug therapy management, we compared PDC and persistence among new users of 6 commonly used chronic medication categories. METHODS: A retrospective analysis of pharmacy claims in a database of more than 64 million members enrolled in 100 health plans assessed persistence and adherence to drug therapy in 6 chronic conditions. Patients were included in the analysis if they initiated a prescription drug of interest in any of 6 drug classes-prostaglandin analogs, statins, bisphosphonates, oral antidiabetics, angiotensin 11 receptor blockers (ARBs), and overactive bladder (DAB) medications-between January 1 and December 31, 2005. The first claim for a drug of interest during this period was considered a patient's index date. Patients were required to have a minimum of 12 months of continuous enrollment both preceding and following their index date. New users of a treatment were identified by excluding patients who filled a prescription for any drug in the same class during the previous 12 months and were followed fora minimum of 12 months. Nonpersistence was defined as discontinuation of the therapy class following an allowed gap between refills-30-, 60-, and 90-day refill gaps were used. Adherence was defined as a continuous measure of the proportion of days covered (PDC) during the 12-month post-index period. Logistic regression analyses predicted (a) nonpersistence during the 12-month post-index period and (b) adherence (PDC) of at least 80%, with drug class as the predictor variable of interest, controlling for demographic variables, insurance and plan type, history of hospitalization, Charlson comorbidity score, copayment for index medication, and number of medications at index. RESULTS: A total of 167,907 patients were identified across 6 cohorts. Using the 60-day gap, 6-month persistence rates were prostaglandin analogs 47%, statins 56%, bisphosphonates 56%, oral antidiabetics 66%, ARBs 63%, and DAB medications 28%. After the first 90 days of therapy, relative persistence was stable across cohorts, and rates declined consistently from 6 months post-index to study end. Logistic regression models showed that oral antidiabetic users had a 59%, 36%, 37%, and 79% decreased risk of nonpersistence in a 12-month follow-up period compared with patients taking prostaglandin analogs, statins, bisphosphonates, or DAB medications, respectively. Risk of nonpersistence decreased with increasing age. Mean (SD) 12-month adherence rates were: prostaglandin analogs 37% (26%), statins 61% (33%), bisphosphonates 60% (34%), oral antidiabetics 72% (32%), ARBs 66% (32%), and DAB medications 35% (32%). Logistic regression indicated that oral antidiabetic use was a significant predictor of adherence (PDC) of at least 80% compared with other therapy classes. Adjusted odds ratios for oral antidiabetics were 17.60 (95% confidence interval [CI] = 15.38-20.14) versus prostaglandin analogs, 2.06 (95% Cl = 1.99-2.12) versus statins, 1.92 (95% Cl = 1.83-2.02) versus bisphosphonates, 1.29 (95% Cl = 1.24-1.34) versus ARBs, and 5.77 (95% Cl = 5.38-6.19) versus DAB medications. CONCLUSION: This analysis of adherence (PDC) and persistence across a sample of 6 chronic therapies found variable but uniformly suboptimal medication use. Adherence to prostaglandin eye drops and DAB medications was lower than to cardiovascular, oral antidiabetic, and oral osteoporosis therapies. These findings provide useful baseline information for the development of initiatives to improve the quality of drug therapy management.
引用
收藏
页码:728 / 740
页数:13
相关论文
共 45 条
[1]  
[Anonymous], 2005, ADHERENCE LONG TERM
[2]  
[Anonymous], 2004, 7 REP JOINT NAT COMM
[3]  
[Anonymous], 2007, ENH PRESCR MED ADH N
[4]  
[Anonymous], 2009, NEHI RES BRIEF
[5]  
[Anonymous], 2004, NAT DIAB FACT SHEET
[6]   Persistence of use of lipid-lowering medications - A cross-national study [J].
Avorn, J ;
Monette, J ;
Lacour, A ;
Bohn, RL ;
Monane, M ;
Mogun, H ;
LeLorier, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18) :1458-1462
[7]   Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: A longitudinal cohort study [J].
Balkrishnan, R ;
Bhosle, MJ ;
Camacho, FT ;
Anderson, RT .
JOURNAL OF UROLOGY, 2006, 175 (03) :1067-1071
[8]   Long-term persistence in use of statin therapy in elderly patients [J].
Benner, JS ;
Glynn, RJ ;
Mogun, H ;
Neumann, PJ ;
Weinstein, MC ;
Avorn, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04) :455-461
[9]   Comparison of drug adherence rates among patients with seven different medical conditions [J].
Briesacher, Becky A. ;
Andrade, Susan E. ;
Fouayzi, Hassan ;
Chan, Arnold .
PHARMACOTHERAPY, 2008, 28 (04) :437-443
[10]   Urinary incontinence: Does it increase risk for falls and fractures? [J].
Brown, JS ;
Vittinghoff, E ;
Wyman, JF ;
Stone, KL ;
Nevitt, MC ;
Ensrud, KE ;
Grady, D .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (07) :721-725